Soleno reports FY2024 net loss of $175.9M; cash $318.6M; PDUFA for DCCR on March 27, 2025

SOLENO THERAPEUTICS INC

2024-FY EPS reported -$4.38

Net loss $(175.9)M ($4.38/share) vs $(39.0)M in 2023; R&D expense $78.6M, G&A $105.9M.
Cash, cash equivalents and marketable securities $318.6M at Dec 31, 2024; used $69.1M in operations.
NDA for DCCR (PWS) under FDA Priority Review with PDUFA target March 27, 2025.
Entered loan agreement with Oxford for up to $200M ($50M upfront); completed $158.7M public offering in May 2024.
Appointed Dawn Carter Bir to Board; Matthew Pauls as Lead Independent Director.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.